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Nebivolol, a Vasodilating
Selective 1-Blocker, Is a 3-Adrenoceptor
Agonist in the Nonfailing Transplanted Human Heart
Bertrand Rozec, MD, PHD,*†‡§ Mortéza Erfanian, BS,*†‡§ Karine Laurent, BS,*†‡§
Jean-Noël Trochu, MD, PHD,*†‡§ Chantal Gauthier, PHD*†‡§
Nantes, France
Objectives The present study was to assess whether nebivolol could activate 3-adrenergic receptors (ARs) in the human
heart.
Background Nebivolol is a third-generation -blocker used in the treatment of heart failure. It associates selective 1-
adrenergic antagonist properties with endothelial and nitric oxide (NO)-dependent vasodilation. Several studies
reported that this vasodilation could result from an activation of 3-ARs, but no data are available in the heart.
Methods The effect of nebivolol (0.1 nmol/l to 10 mol/l) upon the developed peak tension was tested in endomyocar-
dial biopsies from human nonrejecting transplanted hearts. Tension was recorded at steady state using a
mechanoelectric force transducer.
Results Nebivolol induced a concentration-dependent decrease in peak tension (maximum effect obtained at 10 mol/l:
55  4%, n  6), which was similar to that obtained with a preferential 3-AR agonist, BRL 37344 (maximum
effect obtained at 1 mol/l: 45  2%, n  12). The nebivolol effect was not modified by 10 mol/l nadolol, a
1,2-AR antagonist, but was significantly reduced in the presence of 1 mol/l L-748,337, a selective 3-AR an-
tagonist, and after pre-treatment with 100 mol/l NG-monomethyl-L-arginine, an NOS inhibitor.
Conclusions Our study demonstrated that nebivolol activated 3-AR in the human ventricle. The NO-dependent negative ino-
tropic effect of nebivolol associated with its vasodilating properties previously described in human microcoronary
arteries could improve the energetic balance in heart. Those effects could explain the improvement of hemody-
namic parameters obtained in patients with heart failure after nebivolol administration as previously described
in clinical trials. (J Am Coll Cardiol 2009;53:1532–8) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.11.057o
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in the heart, at least 3 populations of -adrenergic receptors
ARs) potentially modulate the cardiac function. The effects of
1- and 2-ARs are well established both in humans and other
ammals. Their stimulation produces positive chronotropic
nd inotropic effects. The first characterization of 3-AR was
erformed in the human heart in 1996 (1). 3-AR stimulation
roduces a negative inotropic effect opposite to that induced by
1- and 2-ARs, involving the nitric oxide synthase (NOS)
athway (2). The presence of 3-AR in ventricles from
onfailing human hearts has been confirmed by the detection
rom the *INSERM, UMR915, l’institut du thorax, Nantes, France; †CNRS,
RL3147, Nantes, France; ‡Université de Nantes, Nantes, France; §CHU Nantes,
’institut du thorax, Nantes, France; and the Department of Anaesthesiology, CHU
antes, Nantes, France. This work was supported by grants from Menarini Interna-
ional, “Fédération Française de Cardiologie,” “Fondation de France,” and “Fondation
anglois.”i
Manuscript received May 27, 2008; revised manuscript received November 20,
008, accepted November 24, 2008.f transcripts by reverse-transcriptase polymerase chain reac-
ion assays (1) and proteins by western blotting and immuno-
istochemistry (3). In the normal heart, it has been suggested
hat 3-AR stimulation might play a role of a “safety valve”
uring intense adrenergic stimulation.
See page 1539
Chronic heart failure is associated with a progressive activa-
ion of the sympathetic nervous system, albeit a failing heart
as a diminished positive inotropic response to -AR stimu-
ation due, at least in part, to a selective down-regulation of
1-AR and desensitization of 1- and 2-ARs (4). Conversely,
ll studies agree that 3-ARs are up-regulated in heart failure
s demonstrated in humans (3), in cardiomyocytes from dogs
ith pacing-induced cardiac heart failure (5), and in rats (6). It
s admitted that at first, the increased cardiac adrenergic drive
s beneficial, but is ultimately damaging to the myocardium.
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April 28, 2009:1532–8 Nebivolol, a 3-AR Agonist in the Human Heartased on those data and on several clinical studies
MERIT-HF [Metoprolol CR/XL Randomised Intervention
rial in Congestive Heart Failure], CIBIS-II [Cardiac Insuf-
ciency Bisoprolol Study II], COPERNICUS [Carvedilol
rospective Randomized Cumulative Survival Study], and
ENIORS [Study of the Effects of Nebivolol Intervention on
utcomes and Rehospitalisation in Seniors with Heart Fail-
re]) (7–10), the new guidelines for management of chronic
ongestive heart failure include broader, stronger recommen-
ations for -blocker therapy (11). Nevertheless, complete
echanisms underlying the beneficial effects of -blockers
emain to be extensively studied. -blockers used in clinical
rials belong either to second generation compounds (cardio-
elective -blockers: metoprolol, bisoprolol) or to more re-
ently developed vasodilating -blockers (carvedilol, nebivo-
ol). -blockers with vasodilatory properties may be superior
ompared to nonvasodilatory -blockers in treating heart
ailure because arteriolar dilation would reduce afterload to the
ailing heart (12). The mechanisms that mediate the beneficial
ffects of nebivolol in patients with chronic heart failure remain
ontroversial, albeit the 1- and 3-ARs have been shown to
e involved. However, the involvement of 3-AR in the
eneficial effect of nebivolol has been only described in vessels.
ebivolol induces a vasodilation in rat thoracic aorta (13) and
uman coronary artery (14) through activation of the nitric
xide (NO) pathway. Conversely, very few works focused on
he cardiac 3-AR targets of nebivolol and they were per-
ormed in mice (15). Thus, the aim of our study was: 1) to
etermine and characterize the involvement of human cardiac
3-AR in the effects of nebivolol; and 2) to compare the
harmacological profile of nebivolol to that of a preferential
3-AR agonist, BRL 37344.
ethods
uman ventricular biopsies. All protocols were approved
y the local ethics committee. Fifty-two human endomyocar-
ial biopsies were obtained from the right interventricular
eptum of cardiac transplant patients (41 men and 5 women)
fter their informed consent. Biopsies were systematically
erformed in the follow-up of the heart transplant patients.
nder local anesthesia, a biotome was introduced percutane-
usly through the right jugular vein to the right ventricle using
-ray guidance; 6 biopsies were taken from the right ventric-
lar septum, and 1 biopsy out of 6 was used for the present
tudy. None of the patients showed evidence of cardiac
ejection, and no adverse event related to the procedure was
eported. All received immunosuppressive therapy (tacroli-
us, prednisolone, mycophenolate mofetil, or cyclospor-
ne). In addition, some of them received cardiovascular
reatment (calcium antagonist, -adrenoceptor antagonist,
-adrenoceptor antagonist, diuretic, digoxin) (Table 1). In
rder to follow the rejection, biopsies are harvested at different
imes after the transplantation. Thus, in some cases (n 4) of our
tudy, several biopsies were obtained from the same patient. REndomyocardial biopsies are
mall (wet weight being about 3 to
mg) with various shapes depend-
ng on forceps insertion in the
ight ventricular septum. The par-
llel arrangement of myocardial
bers in septal endomyocardial
iopsies is not present. These
haracteristics (size and fiber ori-
ntation) contrast with human
picardial and papillary muscle
reparations classically used in
ontractile force measurement. These latter samples are fre-
uently obtained from explanted heart.
sometric force of contraction measurements. The exper-
ments were performed as previously described (16). Briefly,
issues were placed in a transport solution containing (in
mol/l) 120 NaCl, 5 KCl, 1 CaCl2, 1.1 MgCl2, 0.33
aH2PO4, 5 glucose, and 10 Hepes (pH being adjusted to 7.4
ith NaOH) and quickly conveyed to the laboratory. Prepa-
ations were then placed in an experimental chamber and
uperfused at a flow rate of 5 ml/min with oxygenated (95%
2, 5% CO2) Tyrode’s solution (37  0.5°C) composed as
ollows (in mmol/l): 120 NaCl, 5 KCl, 2.7 CaCl2, 1.1 MgCl2,
.33 NaH2PO4, 5 glucose, and 27 NaHCO3. Tissues were
ubjected to field stimulation at a frequency of 0.6 Hz.
reparations were equilibrated for 60 min and subjected to
eld stimulation at pacing cycle length of 1,700 ms using
quare-wave pulses of 1- to 2-ms duration, and amplitude was
wice the diastolic threshold. Mechanical tension was recorded
sing a mechanoelectric force transducer (Akers, AE 801,
ensoNor, Horten, Norway). After a 60-min equilibration
eriod, endomyocardial biopsies were stretched stepwise
10-m increments) to a length at which contraction force was
aximal. The cumulative concentration-response curves of
gonists were then determined by superfusion with successive
ncreasing concentrations of the drugs. For all concentrations,
ension was measured at steady state using a digital storage
scilloscope (model 400, Gould, Les Ullis, France), a strip
hart recorder (model 8188, Gould), and a digital tape recorder
model DTR-1200, Biologic, Claix, France).
linical Characteristics of Patients
Table 1 Clinical Characteristics of Patients
Patients (n  46)
Age (yrs) 51 12
Sex ratio (M/F) 41/5
Ejection fraction (%) 66 9
Drug regimens
-blockers 5
-blockers 7
Diuretics 11
Calcium blockers 8
Angiotensin-converting enzyme inhibitor 8
Digoxin 2
Abbreviations
and Acronyms
AR  adrenergic receptor
eNOS  endothelial nitric
oxide synthase
L-NMMA  NG-monomethyl-
L-arginine
NO  nitric oxide
NOS  nitric oxide
synthaseesults are expressed as mean  SD or absolute value.
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St. Louis, Missouri). NG-monomethyl-L-arginine, mono-
cetate (L-NMMA) was purchased from Calbiochem
La Jolla, California). Nebivolol racemate was a generous
ift from Menarini Research (Firenze, Italy). BRL 37344
4-[-(2-hydroxy-[3-chlorophenyl]ethyl-amino)propyl]
henoxyacetate) was obtained from Research Biochemi-
als Int. (Natick, Massachusetts). L-748,337 was a gen-
rous gift from Merck (Rahway, New Jersey). All drugs
ere prepared as stock solutions in distilled water, with
he exception of: 1) nadolol, which was dissolved in
ydrochloric acid before being neutralized to pH 7.4 with
aOH 1 N; and 2) L-748,337, which was dissolved in
imethyl sulphoxide (Sigma Chemical Co., St. Louis,
issouri). The final concentration of the solvent in the
rgan bath was 0.1% vv1. We have verified that the
olvent had no effect on tension developed by human
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Figure 1 Comparison of Nebivolol and BRL 37344 Effects on B
(A) Superimposed twitches obtained from one representative experiment in the ab
obtained from 1 representative experiment in the absence (CTRL) and the presenc
37344 on contractility developed by human endomyocardial biopsies. For all curve
centage of peak tension measured in control (CTRL). Significant statistical differen
(n  12). There was no significant difference between BRL 37344 (n  12) and nndomyocardial biopsies at the maximal concentration
sed (data not shown).
ata analysis. The results of functional studies are ex-
ressed as mean  SEM of n experiments. The statistical
ignificance of the drug effect was assessed by 1-way analysis
f variance for repeated measurement followed when appro-
riate by a Bonferroni test. Comparison of the concentration-
esponse curves between 2 experimental protocols was per-
ormed by 2-way analysis of variance for repeated measurement
ollowed when appropriate by a Bonferroni test. A value of
 0.05 was considered significant.
esults
omparison of nebivolol and BRL 37344 effects on
uman endomyocardial biopsy. Nebivolol induced a
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April 28, 2009:1532–8 Nebivolol, a 3-AR Agonist in the Human Heartentrations ranging from 0.1 nmol/l to 10 mol/l (Fig. 1C).
ne mol/l of nebivolol decreased peak tension by 55 
.1% (p  0.01, n  6) below the control level. A similar
egative inotropic effect was obtained with a preferential
3-AR agonist, BRL 37344, in the same range of concentra-
ions. The maximum effect induced by BRL 37344 was
btained at a concentration of 1 mol/l, which decreased peak
ension by 45.1 2% (p 0.01, n 12) (Fig. 1C) below the
ontrol level. At higher concentrations, the negative inotropic
ffect induced by BRL 37344 was reduced due to a nonselec-
ive effect. Thus, for the following experiments, we constructed
oncentration-response curves to BRL 37344 for concentra-
ions ranging from 0.1 nmol/l to 1 mol/l.
-AR targets of nebivolol. To determine the specificity
f the -AR targets of nebivolol, a concentration-
esponse curve to nebivolol was also plotted in the
resence of several -AR antagonists. After 20 min of
re-treatment, nadolol, a 1- and 2-adrenoceptor an-
agonist, had no effect on the basal peak tension of
ndomyocardial biopsies. The concentration-response
urve to nebivolol was not modified by 10 mol/l
adolol, perfused before and during all the experiments
Fig. 2A). In the same way, the concentration-response
urve to BRL 37344 was not modified by nadolol (Fig. 2B).
In another set of experiments, the concentration-response
urve to nebivolol was performed in the presence of L-748,337,
selective antagonist of human 3-AR. Twenty minutes of
re-treatment of human endomyocardial biopsies with 1
mol/l L-748,337 did not modify peak tension compared with
ontrol samples. L-748,337 was also perfused during all exper-
ment. In such conditions, the concentration-dependent neg-
tive inotropic effects induced by nebivolol were blunted (Fig.
A). The maximal decrease induced by 10 mol/l nebivolol
as only 19.58  3.97% (p  0.01 vs. nebivolol alone; n 
). Similarly, the concentration-response curve to BRL
7344 was strongly reduced in the presence of 1 mol/l
-748,337 (Fig. 3B). In this condition, peak tension only
ecreased by 15.67  5.60% from control values (p  0.01
s. BRL 37344 alone; n  6).
nvolvement of the NO pathway in the negative inotro-
ic effect of nebivolol. As the NO pathway has been
reviously described in the effect of nebivolol, we have
etermined whether the NOS inhibitor, L-NMMA, mod-
fied the contractile response to nebivolol. L-NMMA had
o significant effect on the basal peak tension of human
ndomyocardial biopsies after 20-min pre-treatment. A
0-min pre-treatment of endomyocardial biopsies with 100
mol/l L-NMMA strongly reduced the negative inotropic
ffect induced by nebivolol (Fig. 4A); 10 mol/l nebivolol
ecreased peak tension by only 21.50  9.7% (n  6) from
ontrol values (p  0.01 vs. nebivolol alone). As illustrated
n Figure 4B, the concentration-response curve to BRL
7344 was reduced by 100 mol/l L-NMMA in a similar
anner. In these conditions, 1 mol/l BRL 37344 de-
reased peak tension by only 21.41  5.01% (p  0.01 vs.
RL 37344 alone, n  4). wiscussion
ur study demonstrated for the first time that nebivolol, a
hird-generation -blocker, activated 3-AR in human heart.
ebivolol by activation of cardiac 3-AR produced like
RL 37344, a preferential 3-AR agonist, a concentration-
ependent negative inotropic effect through activation of
he NO pathway.
In the present work, using a pharmacological approach,
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Figure 2
Negative Inotropic Effect of Nebivolol and BRL
37344 in the Presence of Nadolol, a 1-/2-AR
Antagonist, on Human Endomyocardial Biopsies
Nadolol (10 mol/l) was perfused alone until a steady state was reached (15
to 20 min), and was defined as control. Cumulative concentrations of (A)
nebivolol or (B) BRL 37344 were then perfused in the presence of the antago-
nist. For all curves, values are the mean  SEM of n experiments. Response
is expressed as the percentage of peak tension measured at baseline. There
was no significant difference either between nebivolol  10 mol/l nadolol (n
 6) and nebivolol alone (n  6) or between BRL 37344  10 mol/l nadolol
(n  6) and BRL 37344 alone (n  12).e demonstrated that nebivolol decreased cardiac contrac-
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Nebivolol, a 3-AR Agonist in the Human Heart April 28, 2009:1532–8ility in human endomyocardial biopsies. It is important to
ote that all biopsies used in our study were obtained in
onfailing, nonrejecting transplanted hearts. The mechan-
cal effects of nebivolol were not modified by a pre-
reatment with nadolol, a potent 1- and 2-AR antagonist
ossessing no 3-AR antagonist properties (17,18), indicat-
ng that this effect was not mediated by 1- or 2-AR. By
ontrast, L-748,337, a selective antagonist of human 3-AR
19), strongly reduced the negative inotropic effects induced
y nebivolol. It is important to note that in humans, after
he standard dose of 5 mg, nebivolol has a Cmax of 1.48
g/ml equivalent to 3.3 nmol/l (20). This concentration still
roduced a 15% to 20% reduction of cardiac peak tension
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Figure 3
Negative Inotropic Effect of Nebivolol and BRL 37344
in the Presence of L-748,337, a Selective 3-AR
Antagonist, on Human Endomyocardial Biopsies
L-748,337 (1 mol/l) was perfused alone until a steady state was reached (15
to 20 min), and was defined as control. Cumulative concentrations of (A)
nebivolol (n  6) or (B) BRL 37344 (n  6) were then perfused in the pres-
ence of the antagonist. For all curves, values are the means  SEM of n
experiments. Response is expressed as the percentage of peak tension mea-
sured at baseline. **p  0.01, which indicates significant statistical differ-
ences from nebivolol alone (n  6) or BRL 37344 alone (n  12).ess marked than the decrease produced at micromolaroncentration. To strengthen the action of nebivolol on
ardiac 3-AR, we have compared the effects of nebivolol to
hose induced by BRL 37344, a preferential 3-AR agonist.
oth compounds produced a similar concentration-
ependent negative inotropic effect. The contractile effects
f BRL 37344 were not modified by nadolol but blunted by
-748,337. Our results obtained with BRL 37344 corrob-
rated previous data from our group performed in human
ndomyocardial biopsies (1). In our previous study, we have
sed another 3-AR antagonist, bupranolol, a nonselective
-AR antagonist, which was less efficient than L-748,337
o antagonize the BRL 37344 effects (1).
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Figure 4
Negative Inotropic Effect of Nebivolol and BRL 37344
in the Presence of L-NMMA, a Nonselective NOS
Inhibitor, on Human Endomyocardial Biopsies
NG-monomethyl-L-arginine (L-NMMA) (100 mol/l) was perfused alone until a
steady state was reached (15 to 20 min), and was defined as control. Cumula-
tive concentrations of (A) nebivolol (n  6) or (B) BRL 37344 (n  4) were
then perfused in the presence of the antagonist. For all curves, values are the
means  SEM of n experiments. Response is expressed as the percentage of
peak tension measured at baseline. **p  0.01, which indicates signifi-
cant statistical differences from nebivolol alone (n  6) or BRL 37344
alone (n  12).
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April 28, 2009:1532–8 Nebivolol, a 3-AR Agonist in the Human HeartOur study is the first to describe nebivolol’s effect on
uman ventricular contractility in basal conditions. Previous
tudies have reported the lack of inverse agonistic (21) or
ntrinsic sympathomimetic (22) activity of nebivolol in the
uman heart. Unfortunately, none of those studies has
valuated the inotropic effects induced by nebivolol under basal
onditions or without cyclic adenosine monophosphate-
ependent pre-stimulation (with isoproterenol or forskolin).
n addition, it is important to mention that our samples
ere harvested from nonischemic heart and were used after
short time of transportation to the laboratory, whereas in
ther functional studies, left ventricular myocardium tissues
ere obtained from explanted failing hearts or explanted
earts that could not be used for transplantation. In both
ases, even in the latter one, ischemia could modify func-
ional responses. In human atria, 3-AR has been also
escribed (23). However, nebivolol produced no effect on
ontractility (21), whereas BRL 37344 produced an increase
f contractility. This last positive inotropic effect was
bolished in the presence of nadolol, indicating that BRL
7344 induced this effect through activation of 1-/2-AR
24). These results suggest that regional differences may
xist regarding the functional roles of 3-AR in the human
eart. Those discrepancies could be explained by: 1) a different
ignaling coupling in human atrium and ventricle; and/or 2) a
ifferential 3-AR expression level in atria and ventricle. The
esults of the present work demonstrating an agonistic effect of
ebivolol on 3-AR are in accordance with previous works
erformed in vessels. Indeed, nebivolol stimulated 3-AR in
at aorta (13,25), in human umbilical vein endothelial cells
26), and in human and rodent coronary arteries (14).
In this study, we demonstrated that the negative inotropic
ffect induced by nebivolol and BRL 37344 was strongly
educed in the presence of an NOS inhibitor, L-NMMA,
uggesting an involvement of the NO pathway in this effect.
hese results corroborate those obtained in vessels, in which
ebivolol, like preferential 3-AR agonists, produced an
ndothelium-dependent vasodilation through activation of
he NO pathway (13,14). This pathway played a major role
n the modulation of contractile function (27). It was
emonstrated in various models that NO attenuates the
1-/2-adrenergic increase in inotropy and chronotropy and
einforces the pre- and post-synaptic vagal control of cardiac
ontraction. By doing so, the NOS protects the heart
gainst excessive stimulation by catecholamines, just as an
endogenous -blocker.” In addition, recently it was sug-
ested that 3-AR could be considered by its cellular
ocalization in cardiomyocyte and its coupling to NOS as a
ocal feedback control loop by counteracting cyclic adeno-
ine monophosphate generation obtained via 1-/2-AR
timulation (28). However, the NOS isoforms involved in
he negative inotropic effect induced by nebivolol or 3-AR
gonists remain to be determined. Indeed, some studies
eported endothelial nitric oxide synthase (eNOS) activation
y 3-AR agonists (2,3), whereas recently a potential
ctivation of the neuronal NOS was suggested in diabetic iat myocardium (29). Surprisingly, a recent study using
ebivolol described a new putative 3-AR pathway in mice,
nvolving the inducible NOS even in the absence of cardio-
ascular pathology (15). In our previous works, we demon-
trated on human endomyocardial biopsies the presence of
bundant eNOS but not inducible NOS protein in sections
2). Brixius et al. (30) suggested by immunostaining exper-
ments that eNOS activation by a preferential 3-AR
gonist, BRL 37344, differs between right atrial and left
entricular human myocardium: the translocation of eNOS
as predominant in atrium and phosphorylation of eNOS
n the left ventricle. Moreover, the same group suggests by
mmunohistochemical stainings that nebivolol did not acti-
ate eNOS in nonfailing human myocardium and even
uppressed eNOS activity in the failing heart (31). Then,
uture works will have to be performed to clarify the role of
ifferent NOS isoforms in the mechanical effects induced by
3-AR agonists and/or nebivolol.
The use of human endomyocardial biopsies harvested
rom the denervated heart of patients receiving immuno-
uppressive drugs constitutes an important limitation in our
tudy. Indeed, both conditions could induce modification in
ardiac gene expression and thus directly influence or not
nfluence the -AR system. Nevertheless, as heart failure
nd rejection would have hampered proper interpretation,
hese 2 conditions were not present in our study.
Several large randomized trials and meta-analyses have pro-
ided clear evidence that -blockers reduce the risk of
eath about 30% in chronic heart failure patients (32).
etoprolol, bisoprolol, and carvedilol have been success-
ully evaluated respectively in the MERIT-HF, CIBIS-II, and
OPERNICUS trials (7–9). Recently, nebivolol was eval-
ated in the SENIORS trial, which concluded that nebivo-
ol was effective and well tolerated in elderly heart failure
atients (10). Our results demonstrate in human heart that
ebivolol possesses 3-AR agonistic properties in addition
o well-described, selective 1-AR antagonistic properties
22). Both simultaneous action of nebivolol on 1- and
3-ARs could play a major role in cardiac pathologies in
hich the 1- and 3-AR expressions are modified. It is the
ase in the human failing left ventricle, which is character-
zed by opposite changes occurring in 1- and 3-AR (2- to
-fold increase in 3-ARs) abundance, with an imbalance
etween their inotropic influences. In this context, taking into
ccount this original and specific pharmacological -AR pro-
le, nebivolol can be of particular interest in heart failure and
ay account for additive beneficial effects through several
echanisms. In particular, the stimulation of 3-AR could
articipate in the myocardium protection: 1) by a reduction of
he activation of L-type calcium channels (33) and, thus, of
alcium overload; 2) by a better diastolic function due to
ncreased NO production; and finally, 3) by the vasodilating
ffects, because arteriolar dilation would reduce afterload and
ncrease coronary blood flow.
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his study gives more insight into the pharmacological
roperties of nebivolol, a -blocker of the third generation,
y demonstrating the affinity of nebivolol for 3-ARs in the
uman heart. The NO-dependent negative inotropic effect
f nebivolol associated with its vasodilating properties pre-
iously described in human microcoronary arteries could
mprove the energetic balance in heart. Those effects could
xplain the improvement of hemodynamic parameters ob-
ained in patients with heart failure after nebivolol admin-
stration, as previously described in clinical trials.
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